Soligenix receives fda ind clearance for phase 2 clinical trial of synthetic hypericin in the treatment of psoriasis

Enrollment on track to begin in 4th   quarter of 2022 princeton, n.j. , june 28, 2022 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the u.s. food and drug administration (fda) has cleared the investigational new drug (ind) application for a phase 2a clinical trial titled, "phase 2 study evaluating sgx302 in the treatment of mild-to-moderate psoriasis.
SNGX Ratings Summary
SNGX Quant Ranking